Selective side-chain modification of cysteine and arginine residues blocks pathogenic activity of HIV-1-Tat functional peptides

[1]  S. Muller,et al.  A synthetic HIV‐1 Tat protein breaches the skin barrier and elicits Tat‐neutralizing antibodies and cellular immunity , 2004, European journal of immunology.

[2]  K. M. Mohankumar,et al.  Codon Optimization of the Tat Antigen of Human Immunodeficiency Virus Type 1 Generates Strong Immune Responses in Mice following Genetic Immunization , 2004, Journal of Virology.

[3]  F. Bussolino,et al.  Human Immunodeficiency Virus Type 1 Tat Regulates Endothelial Cell Actin Cytoskeletal Dynamics through PAK1 Activation and Oxidant Production , 2004, Journal of Virology.

[4]  Yong Woo Lee,et al.  HIV-1 tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain , 2003, Molecular and Cellular Neuroscience.

[5]  Yi-da Yang,et al.  Monocytes Treated with Human Immunodeficiency Virus Tat Kill Uninfected CD4+ Cells by a Tumor Necrosis Factor-Related Apoptosis-Induced Ligand-Mediated Mechanism , 2003, Journal of Virology.

[6]  D. Noonan,et al.  Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers. , 2003, Journal of acquired immune deficiency syndromes.

[7]  Glen S. Hatfield,et al.  Tat-Neutralizing Antibodies in Vaccinated Macaques , 2003, Journal of Virology.

[8]  Kuan-Teh Jeang,et al.  Tat and Trans-activation-responsive (TAR) RNA-independent Induction of HIV-1 Long Terminal Repeat by Human and Murine Cyclin T1 Requires Sp1* , 2003, The Journal of Biological Chemistry.

[9]  Christopher J. Miller,et al.  HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages , 2003, Nature Medicine.

[10]  S. Dhawan,et al.  Human immunodeficiency virus type-1 (HIV-1) Tat protein: mechanisms for activation of host factors and viral pathogenesis. , 2003 .

[11]  K. Khalili,et al.  Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. , 2003, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  M. Magnani,et al.  HIV-1 Tat-based vaccines: from basic science to clinical trials. , 2002, DNA and cell biology.

[13]  Mark G. Lewis,et al.  Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses. , 2002, DNA and cell biology.

[14]  M. Reitz,et al.  A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Mark G. Lewis,et al.  Outcome of Simian-Human Immunodeficiency Virus Strain 89.6p Challenge following Vaccination of Rhesus Macaques with Human Immunodeficiency Virus Tat Protein , 2002, Journal of Virology.

[16]  G. Barillari,et al.  Angiogenic Effects of Extracellular Human Immunodeficiency Virus Type 1 Tat Protein and Its Role in the Pathogenesis of AIDS-Associated Kaposi's Sarcoma , 2002, Clinical Microbiology Reviews.

[17]  M Stürzl,et al.  Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. , 2001, Molecular biology of the cell.

[18]  M. Re,et al.  Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[19]  G. Camussi,et al.  Tat‐induced platelet‐activating factor synthesis contributes to the angiogenic effect of HIV‐1 Tat , 2001, European journal of immunology.

[20]  Kenneth M. Yamada,et al.  Immunization with a novel HIV-1-Tat multiple-peptide conjugate induces effective immune response in mice , 2000, Peptides.

[21]  C. Tacchetti,et al.  Human immunodeficiency virus transactivator protein (Tat) stimulates chemotaxis, calcium mobilization, and activation of human polymorphonuclear leukocytes: implications for Tat-mediated pathogenesis. , 2000, The Journal of infectious diseases.

[22]  M. Benkirane,et al.  Tat Protein of Human Immunodeficiency Virus Type 1 Induces Interleukin-10 in Human Peripheral Blood Monocytes: Implication of Protein Kinase C-Dependent Pathway , 2000, Journal of Virology.

[23]  H. Nakhasi,et al.  Synthesis and construction of a novel multiple peptide conjugate system: strategy for a subunit vaccine design , 2000, Peptides.

[24]  M. Giacca,et al.  Identification of Specific Molecular Structures of Human Immunodeficiency Virus Type 1 Tat Relevant for Its Biological Effects on Vascular Endothelial Cells , 2000, Journal of Virology.

[25]  A. Burny,et al.  Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Weiss,et al.  HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. , 1999, Journal of immunology.

[27]  A. Nel,et al.  Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. , 1999, Journal of immunology.

[28]  G. Barillari,et al.  The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. , 1999, Blood.

[29]  U. Shankavaram,et al.  Cutting edge: a short polypeptide domain of HIV-1-Tat protein mediates pathogenesis. , 1999, Journal of immunology.

[30]  E. Major,et al.  Transient Exposure to HIV-1 Tat Protein Results in Cytokine Production in Macrophages and Astrocytes , 1999, The Journal of Biological Chemistry.

[31]  R. Sitia,et al.  HIV-I Tat: a polypeptide for all seasons. , 1998, Immunology today.

[32]  Irene Bosch,et al.  Tat Protein Induces Human Immunodeficiency Virus Type 1 (HIV-1) Coreceptors and Promotes Infection with both Macrophage-Tropic and T-Lymphotropic HIV-1 Strains , 1998, Journal of Virology.

[33]  S. Manna,et al.  HIV-Tat protein activates c-Jun N-terminal kinase and activator protein-1. , 1998, Journal of immunology.

[34]  Zhong-ying Liu,et al.  Human Immunodeficiency Virus Tat Modulates the Flk-1/KDR Receptor, Mitogen-Activated Protein Kinases, and Components of Focal Adhesion in Kaposi’s Sarcoma Cells , 1998, Journal of Virology.

[35]  D. Noonan,et al.  Identification of a Novel Domain of HIV Tat Involved in Monocyte Chemotaxis* , 1998, The Journal of Biological Chemistry.

[36]  N. Kamada,et al.  Mechanisms of growth control of Kaposi's sarcoma-associated herpes virus-associated primary effusion lymphoma cells. , 1998, Blood.

[37]  E. Verdin,et al.  Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-kappaB factors. , 1998, Journal of immunology.

[38]  W. Marasco,et al.  Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat. , 1998, Human gene therapy.

[39]  K. Yamada,et al.  Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. , 1997, Journal of immunology.

[40]  R. Puri,et al.  Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. , 1997, Blood.

[41]  C. Van Lint,et al.  Immune Hyperactivation of HIV-1-Infected T Cells Mediated by Tat and the CD28 Pathway , 1997, Science.

[42]  R. Soldi,et al.  The angiogenesis induced by HIV–1 Tat protein is mediated by the Flk–1/KDR receptor on vascular endothelial cells , 1996, Nature Medicine.

[43]  I. Hewlett,et al.  HIV-1-Tat protein promotes chemotaxis and invasive behavior by monocytes. , 1996, Journal of immunology.

[44]  M. Giacca,et al.  Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[45]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[46]  G. Zauli,et al.  Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients , 1996, Clinical and diagnostic laboratory immunology.

[47]  I. Hewlett,et al.  HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis. , 1996, Journal of immunology.

[48]  A. Albini,et al.  Angiogenic properties of human immunodeficiency virus type 1 Tat protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[49]  A. Heredia,et al.  Interferon-gamma-induced downregulation of CD4 inhibits the entry of human immunodeficiency virus type-1 in primary monocytes. , 1995, Pathobiology : journal of immunopathology, molecular and cellular biology.

[50]  P. Wingfield,et al.  Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation , 1993, Journal of virology.

[51]  L. Buonaguro,et al.  Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines , 1992, Journal of virology.

[52]  F. Kashanchi,et al.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro. , 1992, Gene expression.

[53]  S. Salahuddin,et al.  Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients , 1990, Nature.

[54]  J. Justement,et al.  Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. , 1987, Science.

[55]  J. Sodroski,et al.  The trans-activator gene of the human T cell lymphotropic virus type III is required for replication , 1986, Cell.

[56]  S. Wahl,et al.  Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). I. Characterization of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions by flow cytometric analysis. , 1984, Cellular immunology.